Honey bee as apitoxin, carries several active components, the most abundant of which is melittin, and the most biologically active are enzymes, particularly phospholipase A2. Bee venom is under laboratory and clinical research for its potential properties and uses in reducing risks for adverse events from bee venom therapy, rheumatoid arthritis, and use as an immunotherapy for protection against allergies from insect stings. Bee venom products are marketed in many countries, but, as of 2018, there are no approved clinical uses for these products which carry various warnings for potential allergic reactions. With an increased number of honey bees in a specific
Venom optimization hypothesis Venom optimization hypothesis Venom optimization hypothesis, also known as venom metering, is a biological hypothesis which postulates that venomous animals have physiological control over their production and use of venoms. It explains the economic use of venom because venom is a metabolically expensive product, and that there is a biological mechanism for controlling their specific use. The hypothetical concept was proposed by Esther Wigger, Lucia Kuhn-Nentwig, and Wolfgang Nentwig of the Zoological Institute at the University of Bern, Switzerland, in 2002. A number of venomous animals have been experimentally found to regulate the amount of venom they use during predation